ABVC BioPharma files AIBL audited financials: zero revenue, $598K deficit, going concern

ABVC BIOPHARMA, INC.

AIBL had no revenue, $597,886 accumulated deficit, and zero cash as of Sep 30, 2023.
Pro forma combined net loss for nine months ended Sep 30, 2023 was $8.18M, vs ABVC standalone $7.58M.
ABVC and BioLite each received 23M AIBL shares at $10/share, giving ABVC controlling interest.
Licensed products for MDD/ADHD valued at $667M by third party; potential milestones of $3.5M plus 5% royalties.
Auditor expresses substantial doubt about AIBL's ability to continue as a going concern.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.